LOX-1: A potential driver of cardiovascular risk in SLE patients-Reference-Cited by-同舟云学术

LOX-1: A potential driver of cardiovascular risk in SLE patients

Published:2020-03-17 Issue:3 Volume:15 Page:e0229184
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Sagar Divya,Gaddipati Ranjitha,Ongstad Emily L.,Bhagroo Nicholas,An Ling-Ling,Wang Jingya,Belkhodja Mehdi,Rahman Saifur,Manna Zerai,Davis Michael A.,Hasni Sarfaraz,Siegel Richard,Sanjuan Miguel,Grimsby Joseph,Kolbeck Roland,Karathanasis Sotirios,Sims Gary P.^ORCID,Gupta Ruchi

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference75 articles.

1. Premature coronary-artery atherosclerosis in systemic lupus erythematosus;Y Asanuma;N Engl J Med,2003

2. Cardiovascular disease in systemic lupus erythematosus: the role of traditional and lupus related risk factors;CB Zeller;Curr Cardiol Rev,2008

3. The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review;SR Schoenfeld;Semin Arthritis Rheum,2013

4. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus;JM Esdaile;Arthritis Rheum,2001

5. Cardiovascular risk in systemic lupus erythematosus—evidence of increased oxidative stress and dyslipidaemia;SL Nuttall;Rheumatology (Oxford),2003

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring the Association Between Systemic Lupus Erythematosus and High‐Density Lipoproteins: A Systematic Review and Meta‐Analysis;ACR Open Rheumatology;2024-07-19

2. LOX-1 and MMP-9 Inhibition Attenuates the Detrimental Effects of Delayed rt-PA Therapy and Improves Outcomes After Acute Ischemic Stroke;Circulation Research;2024-04-12

3. An update on cardiovascular disorders in systemic lupus erythematosus;Advances in Clinical and Experimental Medicine;2024-03-12

4. Whole blood coagulation in an ex vivo thrombus is sufficient to induce clot neutrophils to adopt a myeloid-derived suppressor cell signature and shed soluble Lox-1;Journal of Thrombosis and Haemostasis;2023-12

5. LOX-1 and MMP-9 inhibition attenuates the detrimental effects of delayed rt-PA therapy and improves outcomes after acute ischemic stroke;2023-08-15